Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study
Journal of Hypertension, 04/16/2012Dusing R et al.
Aliskiren showed a greater and more sustained blood pressure (BP)–lowering effect than telmisartan during a 7–day treatment withdrawal. Aliskiren may provide sustained BP lowering during 1 day or more missed dose.
Patients were randomized to once–daily aliskiren 150mg (N=414) or telmisartan 40mg (N=408).
After 2 weeks, all patients were uptitrated to double the initial dose for 10 weeks; subsequently, all patients were treated with placebo to simulate a 7–day treatment withdrawal.
At the end of active treatment (EoA), similar decreases in mean ambulatory BP were observed with aliskiren and telmisartan. From EoA to day 7 of treatment withdrawal (end of withdrawal, EoW), the least squares mean increase in 24–h mean ambulatory SBP was smaller for aliskiren (2.7mmHg) vs. telmisartan (6.5mmHg).
Between–treatment difference was significant in favour of aliskiren (–3.8mmHg; P<0.0001).
Similar effects were observed for the increase in 24–h mean ambulatory DBP after EoW (–2.1mmHg; P<0.0001).
Mean sitting SBP and DBP were also significantly lower with aliskiren than telmisartan after EoW with SBP (2.0mmHg) and DBP (1.1mmHg) differences in favour of aliskiren, already evident on day 2 after a single 'missed dose'.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.